September 11, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares over potential securities laws violations by Alnylam Pharmaceuticals and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) concerning whether a series of statements by Alnylam Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambrdige, MA based Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. Alnylam Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $41.10 million in 2015 to $47.16 million in 2016 and that its Net loss increased from $290.07 million in 2015 to $410.11 million in 2016.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew from $31.41 per share in late 2016 to as high as $89.29 per share on September 1, 2017.


On September 7, 2017, Alnylam Pharmaceuticals, Inc. advised investors that the Company had stop giving doses of fitusiran, Alnylam's experimental hemophilia treatment, to patients enrolled in the Company's clinical studies, following the death of a patient who developed a blood clot.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) declined on September 8, 2017 to $70.92 per share.